Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

Supportive Care ◽

Controlled Trial ◽

Best Supportive Care ◽

Small Cell ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind ◽

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(13)70586-2 ◽

2014 ◽

Vol 15 (2) ◽

pp. 143-155 ◽

Cited By ~ 496

Author(s):

Martin Reck ◽

Rolf Kaiser ◽

Anders Mellemgaard ◽

Jean-Yves Douillard ◽

Sergey Orlov ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind ◽

Previously Treated ◽

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(16)32517-x ◽

2017 ◽

Vol 389 (10066) ◽

pp. 255-265 ◽

Cited By ~ 1731

Author(s):

Achim Rittmeyer ◽

Fabrice Barlesi ◽

Daniel Waterkamp ◽

Keunchil Park ◽

Fortunato Ciardiello ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Previously Treated ◽

Fortis-M, a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Oral Talactoferrin Alfa with Best Supportive Care in Patients with Advanced Non-Small Cell Lung Cancer Following Two or More Prior Regimens- by the Fortis-M Study Group

Annals of Oncology ◽

10.1016/s0923-7534(20)34343-x ◽

2012 ◽

Vol 23 ◽

pp. ixe23 ◽

Cited By ~ 1

Author(s):

S.S. Ramalingam ◽

J. Crawford ◽

A. Chang ◽

C. Manegold ◽

R. Perez-Soler ◽

...

Keyword(s):

Lung Cancer ◽

Supportive Care ◽

Small Cell Lung Cancer ◽

Best Supportive Care ◽

Small Cell ◽

Study Group ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(18)30896-9 ◽

2019 ◽

Vol 20 (4) ◽

pp. 494-503 ◽

Cited By ~ 110

Author(s):

David Ball ◽

G Tao Mai ◽

Shalini Vinod ◽

Scott Babington ◽

Jeremy Ruben ◽

...

Keyword(s):

Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Stereotactic Ablative Radiotherapy ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Randomised Controlled ◽

Stage 1

A phase III multi-centre randomised controlled trial to assess whether optimal supportive care alone (including dexamethasone) is as effective as optimal supportive care (including dexamethasone) plus whole brain radiotherapy in the treatment of patients with inoperable brain metastases from non-small cell lung cancer

http://isrctn.org/> ◽

10.1186/isrctn13826061 ◽

2013 ◽

Author(s):

Paula Mulvenna

Keyword(s):

Lung Cancer ◽

Supportive Care ◽

Controlled Trial ◽

Whole Brain Radiotherapy ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Brain Radiotherapy ◽

Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(14)61085-0 ◽

2015 ◽

Vol 385 (9962) ◽

pp. 36-42 ◽

Cited By ~ 229

Author(s):

Ben J Slotman ◽

Harm van Tinteren ◽

John O Praag ◽

Joost L Knegjens ◽

Sherif Y El Sharouni ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Thoracic Radiotherapy ◽

Small Cell Lung ◽

Phase 3 ◽

Extensive Stage ◽

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

The Lancet ◽

10.1016/s0140-6736(09)61497-5 ◽

2009 ◽

Vol 374 (9699) ◽

pp. 1432-1440 ◽

Cited By ~ 796

Author(s):

Tudor Ciuleanu ◽

Thomas Brodowicz ◽

Christoph Zielinski ◽

Joo Hang Kim ◽

Maciej Krzakowski ◽

...

Keyword(s):

Lung Cancer ◽

Supportive Care ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Best Supportive Care ◽

Small Cell ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind

Benefits of home-based multidisciplinary exercise and supportive care in inoperable non-small cell lung cancer – protocol for a phase II randomised controlled trial

BMC Cancer ◽

10.1186/s12885-017-3651-4 ◽

2017 ◽

Vol 17 (1) ◽

Cited By ~ 11

Author(s):

Lara Edbrooke ◽

Sanchia Aranda ◽

Catherine L. Granger ◽

Christine F. McDonald ◽

Mei Krishnasamy ◽

...

Keyword(s):

Lung Cancer ◽

Supportive Care ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Controlled Trial ◽

Small Cell ◽

Small Cell Lung ◽

Home Based ◽

1453P Early interdisciplinary supportive care in patients with non-small cell lung cancer: A randomised controlled trial

Annals of Oncology ◽

10.1016/j.annonc.2021.08.218 ◽

2021 ◽

Vol 32 ◽

pp. S1080

Author(s):

M. Chen ◽

H. Yu ◽

L. Yang ◽

S. Wang ◽

...

Keyword(s):

Lung Cancer ◽

Supportive Care ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Small Cell Lung ◽

Faculty Opinions recommendation of Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718047126.793482089 ◽

2013 ◽

Author(s):

Thomas Stinchcombe

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

Small Cell Lung ◽